Vol. 5 No. 9 (2025)
Reimbursement Recommendations

Abemaciclib (Verzenio)

Published September 15, 2025

Key Messages

  • Canada’s Drug Agency (CDA-AMC) recommends that Verzenio plus fulvestrant be reimbursed by public drug plans for the treatment of hormone receptor (HR)–positive, HER2-negative advanced or metastatic breast cancer in combination with fulvestrant for patients with disease progression following endocrine therapy if certain conditions are met.
  • Verzenio plus fulvestrant should only be covered to treat adults with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. Verzenio plus fulvestrant should not be covered for patients who have previously received cyclin-dependent kinase (CDK) 4 or CDK6 inhibitors in the metastatic setting, more than 1 line of chemotherapy or more than 1 line of endocrine therapy, or treatment with fulvestrant.
  • Verzenio plus fulvestrant should only be reimbursed if prescribed under the care of clinicians with expertise in the treatment of advanced breast cancer, and if the cost of Verzenio for the indicated population does not exceed the drug program cost of treatment with ribociclib, both in combination with fulvestrant.